CMS certification 454076
Harris County Psychiatric Center
2800 Macgregor Way, Houston, TX 77021
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
Clinicians registered at this address
87 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 8 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Psychiatry | 31 |
| Psychiatric/Mental Health | 27 |
| Clinical | 13 |
| Child & Adolescent Psychiatry | 2 |
| Social Worker | 2 |
| Clinical Child & Adolescent | 1 |
| Community Health/Public Health | 1 |
| Forensic | 1 |
| Geriatric Psychiatry | 1 |
| Health Service | 1 |
| Mental Health | 1 |
| Nurse Practitioner | 1 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $281,422
- 2020 $256,576
- 2021 $217,554
- 2022 $302,863
- 2023 $390,071
- 2024 $628,850
- 2025 $512,965
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Royalties and licensing fees | $67,051 | 4 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $253,171 | 51 |
| Agios Pharmaceuticals, Inc. | $92,857 | 17 |
| Bracco Diagnostics Inc. | $67,051 | 4 |
| Arcutis Biotherapeutics, Inc. | $38,675 | 4 |
| Impulse Dynamics (USA) Inc. | $33,373 | 9 |
| CathWorks, Inc. | $9,620 | 1 |
| United Imaging Healthcare North America, Inc. | $7,855 | 1 |
| Dexcom, Inc. | $6,173 | 3 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle… Agios Pharmaceuticals, Inc. | $92,857 |
| TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate … Takeda Pharmaceuticals U.S.A., Inc. | $71,639 |
| An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous (IV) and Adalimumab Subcutaneo… Takeda Pharmaceuticals U.S.A., Inc. | $42,348 |
| Vedolizumab-4054 A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) Takeda Pharmaceuticals U.S.A., Inc. | $42,348 |
| A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with Atopi… Arcutis Biotherapeutics, Inc. | $38,675 |
| A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITH… Takeda Pharmaceuticals U.S.A., Inc. | $35,006 |
| Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) Impulse Dynamics (USA) Inc. · NCT05064709 | $32,918 |
| TAK-007 in Refractory Lupus Nephritis Takeda Pharmaceuticals U.S.A., Inc. | $31,440 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
Common questions about Harris County Psychiatric Center
Does Harris County Psychiatric Center have an emergency room?
No. CMS does not list emergency services at Harris County Psychiatric Center.
Does Harris County Psychiatric Center receive money from drug and device companies?
Drug and device makers reported $512,965 in payments to Harris County Psychiatric Center for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.